GLP-1 Entry Push Lifts RPG Life Sciences Growth Strategy Shift

RPG Life Sciences is sharpening its strategy today with a strong focus on its GLP-1 entry plan and expanding API business, signaling a shift toward high-growth pharmaceutical segments.

The company is looking to strengthen its position in active pharmaceutical ingredients while preparing to enter the fast-growing diabetes and obesity treatment market.

Management has also indicated interest in a potential large-scale acquisition worth Rs 600–1,000 crore to boost capabilities and scale faster in key therapeutic areas. The move comes as global demand for advanced metabolic drugs continues to rise.

RPG Life Sciences is betting big on its API business, seeing it as a stable revenue base with long-term growth potential. The company aims to develop complex molecules and strengthen manufacturing depth, positioning itself as a reliable supplier in global markets.

Also Read: Consumer Trust in OTC Products: The Science Behind Safety

"We are poised to deliver five products every year ... we have visibility for the next three years and we also have visibility of which markets we should be entering," said Ashok Nair, Managing Director, RPG Life Sciences.

At the same time, the company is preparing for its GLP-1 entry in August–September 2026, targeting injectable semaglutide-based products. This segment has become one of the most competitive and high-demand categories in the global pharmaceutical industry, driven by rising cases of diabetes and obesity.

To support its expansion plans, RPG Life Sciences is also evaluating inorganic growth opportunities. The proposed Rs 600–1,000 crore acquisition could accelerate its presence in complex formulations and improve scale in both domestic and export markets. The dual strategy of stable API growth and high-potential GLP-1 expansion reflects a balanced approach to risk and opportunity.

With both API and specialty drug expansion in focus, the company is positioning itself for a stronger global footprint. Industry watchers see the move as part of a broader trend where Indian pharma firms are shifting toward high-value complex therapies rather than only generics. Execution over the next few quarters, especially around GLP-1 entry, will be critical for future growth momentum.